Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 25, 2026

The "Great Rotation" Out of Tech Is Fading. Here Are the Best Artificial Intelligence (AI) Growth Stocks Poised to Benefit.

View original at finance.yahoo.com
The "Great Rotation" Out of Tech Is Fading. Here Are the Best Artificial Intelligence (AI) Growth Stocks Poised to Benefit. The so-called "Great Rotation" out of tech and artificial intelligence (AI) stocks appears to have been short-lived…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Hyperscalers are increasingly turning to Broadcom as they look to become less reliant on Nvidia

    60% confidence
  • The next phase of AI will be more about inference and AI agents rather than model training

    60% confidence
  • As agentic AI rises, the CPU-to-GPU ratio in AI data centers is about to get much tighter

    60% confidence
  • Broadcom's projected $100 billion in AI chip revenue for FY2027 is approximately 5 times the total AI revenue it produced in the prior year

    60% confidence
  • AMD's chiplet design packs more memory into its chips, differentiating it in the inference GPU market

    60% confidence
  • Broadcom projected it would sell $100 billion in AI chips alone in fiscal year 2027

    60% confidence
  • Growth is still the place to be in equities, and right now the biggest growth is coming from AI

    60% confidence
  • Broadcom is a leader in data center networking with its Tomahawk Ethernet solution and is seeing robust growth in that segment

    60% confidence
  • AMD is the leader in the data center CPU market

    60% confidence
  • The Great Rotation out of tech and AI stocks appears to have been short-lived

    60% confidence
  • AMD's data center CPU business is set to deliver new CPUs designed specifically for agentic AI

    60% confidence

Data points we hold from this source

Anthropic · backlog21 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com